Another new CAR-T cell therapy 'Yescarta' is anticipated to enter the Korean market.

The Ministry of Food and Drug Safety (MFDS) recently posted that it has designated an orphan drug for Gilead Sciences' Yescarta (axicabtagene ciloleucel).

The designated indication will include ▲Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or primary mediastinal B-cell lymphoma (PMBCL) who have undergone two or more systemic treatments ▲Adult patients with DLBCL who have relapsed or refractory within 12 months after the first-line chemoimmunotherapy.

Yescartav is a CAR-T cell therapy that received the first approval from the U.S. Food and Drug Admin